Diabetes mellitus is a major chronic disease epidemic that requires comprehensive and lifelong management from an interprofessional team, with pharmacists playing a central role. Modern diabetes care, as detailed in the Patient Care 5 curriculum, involves a deep understanding of pathophysiology, complex pharmacotherapy ranging from oral agents to injectable insulins and GLP-1 agonists, and the management of its many acute and chronic complications. This quiz will test your knowledge on the evidence-based therapeutic strategies essential for providing optimal care to patients with diabetes.
1. Which of the following is considered first-line pharmacotherapy for a newly diagnosed patient with Type 2 Diabetes, in addition to lifestyle modifications?
- a. Insulin glargine
- b. Glipizide
- c. Metformin
- d. Pioglitazone
Answer: c. Metformin
2. What is the primary mechanism of action for metformin?
- a. It stimulates insulin secretion from the pancreas.
- b. It decreases hepatic glucose production and increases peripheral insulin sensitivity.
- c. It blocks the reabsorption of glucose in the kidneys.
- d. It slows the absorption of carbohydrates from the gut.
Answer: b. It decreases hepatic glucose production and increases peripheral insulin sensitivity.
3. A patient with Type 1 Diabetes must be treated with insulin because:
- a. They are resistant to oral medications.
- b. Their pancreas produces no insulin due to autoimmune destruction of beta cells.
- c. Insulin is cheaper than oral medications.
- d. They have severe insulin resistance.
Answer: b. Their pancreas produces no insulin due to autoimmune destruction of beta cells.
4. Which class of medications works by inhibiting the enzyme responsible for breaking down incretin hormones like GLP-1?
- a. Sulfonylureas
- b. Thiazolidinediones (TZDs)
- c. SGLT2 inhibitors
- d. DPP-4 inhibitors
Answer: d. DPP-4 inhibitors
5. A patient is prescribed insulin lispro. The pharmacist should counsel the patient to inject this insulin:
- a. 30-60 minutes before a meal.
- b. Once daily at bedtime.
- c. Within 15 minutes before or immediately after a meal.
- d. Twice daily, 30 minutes before breakfast and dinner.
Answer: c. Within 15 minutes before or immediately after a meal.
6. The “Management of Diabetes Mellitus” is a specific learning module in which course?
- a. PHA5787C Patient Care 5
- b. PHA5104 Sterile Compounding
- c. PHA5703 Pharmacy Law and Ethics
- d. PHA5878C Patient Care 3
Answer: a. PHA5787C Patient Care 5
7. Sodium-glucose cotransporter 2 (SGLT2) inhibitors, such as empagliflozin, lower blood glucose by:
- a. Increasing insulin secretion.
- b. Increasing urinary excretion of glucose.
- c. Decreasing hepatic glucose output.
- d. Improving insulin sensitivity in muscle tissue.
Answer: b. Increasing urinary excretion of glucose.
8. Which of the following is a major advantage of GLP-1 receptor agonists and SGLT2 inhibitors in the management of type 2 diabetes?
- a. They are all oral medications.
- b. They have a very low risk of hypoglycemia when used as monotherapy.
- c. They have demonstrated cardiovascular and/or renal benefits.
- d. They are the least expensive options.
Answer: c. They have demonstrated cardiovascular and/or renal benefits.
9. A patient taking a sulfonylurea like glipizide is at highest risk for which adverse effect?
- a. Lactic acidosis
- b. Hypoglycemia
- c. Urinary tract infections
- d. Pancreatitis
Answer: b. Hypoglycemia
10. What is the A1c goal for most non-pregnant adults with diabetes?
- a. < 6.0%
- b. < 7.0%
- c. < 8.0%
- d. < 9.0%
Answer: b. < 7.0%
11. The pharmacology of oral and injectable diabetes medications is a specific topic within the Patient Care 5 curriculum.
- a. True
- b. False
Answer: a. True
12. The “Rule of 15” is used to treat:
- a. Diabetic Ketoacidosis (DKA)
- b. A hypertensive crisis
- c. Hypoglycemia
- d. A new diagnosis of diabetes
Answer: c. Hypoglycemia
13. A patient with diabetic nephropathy and albuminuria should be treated with which class of medication for blood pressure control and renal protection?
- a. A beta-blocker
- an ACE inhibitor or an ARB
- c. A non-dihydropyridine calcium channel blocker
- d. A loop diuretic
Answer: b. an ACE inhibitor or an ARB
14. A common side effect of SGLT2 inhibitors is:
- a. Weight gain
- b. Genitourinary fungal infections
- c. Constipation
- d. Hypokalemia
Answer: b. Genitourinary fungal infections
15. Insulin glargine and insulin detemir are classified as what type of insulin?
- a. Rapid-acting
- b. Short-acting
- c. Intermediate-acting
- d. Long-acting
Answer: d. Long-acting
16. Metformin should be used with caution or is contraindicated in patients with:
- a. Hypertension
- b. Dyslipidemia
- c. Severe renal impairment (e.g., eGFR < 30 mL/min/1.73m²).
- d. Asthma
Answer: c. Severe renal impairment (e.g., eGFR < 30 mL/min/1.73m²).
17. The management of diabetes complications is a topic within the Patient Care 5 curriculum.
- a. True
- b. False
Answer: a. True
18. Diabetic Ketoacidosis (DKA) is most commonly associated with:
- a. Type 2 Diabetes
- b. Type 1 Diabetes
- c. Gestational Diabetes
- d. Prediabetes
Answer: b. Type 1 Diabetes
19. A key counseling point for a patient starting a GLP-1 receptor agonist like liraglutide is:
- a. The risk of hypoglycemia is very high.
- b. GI side effects like nausea are common upon initiation and titration.
- c. The injection should be administered intramuscularly.
- d. The medication will cause significant weight gain.
Answer: b. GI side effects like nausea are common upon initiation and titration.
20. An active learning session on diabetes is part of the Patient Care 5 course.
- a. True
- b. False
Answer: a. True
21. Pioglitazone, a thiazolidinedione (TZD), carries a black box warning for:
- a. Lactic acidosis
- b. Causing or exacerbating heart failure.
- c. Thyroid tumors
- d. Severe hypoglycemia
Answer: b. Causing or exacerbating heart failure.
22. A basal-bolus insulin regimen consists of:
- a. Only rapid-acting insulin before meals.
- b. Only a long-acting insulin once a day.
- c. A long-acting (basal) insulin plus a rapid-acting (bolus) insulin with meals.
- d. NPH insulin mixed with regular insulin twice daily.
Answer: c. A long-acting (basal) insulin plus a rapid-acting (bolus) insulin with meals.
23. Educating a patient on how to monitor their blood glucose is a key objective for student pharmacists.
- a. True
- b. False
Answer: a. True
24. Which of the following is a microvascular complication of diabetes?
- a. Coronary artery disease
- b. Stroke
- c. Peripheral artery disease
- d. Retinopathy
Answer: d. Retinopathy
25. A pharmacist counseling a patient on proper insulin injection technique should advise them to:
- a. Use the same injection site every time.
- b. Rotate injection sites to prevent lipohypertrophy.
- c. Inject into a muscle for faster absorption.
- d. Share needles with a family member who also has diabetes.
Answer: b. Rotate injection sites to prevent lipohypertrophy.
26. Which of the following is NOT a diagnostic criterion for diabetes?
- a. A1c ≥ 6.5%
- b. Fasting plasma glucose ≥ 126 mg/dL
- c. 2-hour plasma glucose ≥ 200 mg/dL during an OGTT
- d. Random plasma glucose ≥ 150 mg/dL with no symptoms
Answer: d. Random plasma glucose ≥ 150 mg/dL with no symptoms
27. The primary mechanism of action of sulfonylureas is to:
- a. Increase insulin sensitivity.
- b. Stimulate insulin secretion from pancreatic beta cells regardless of blood glucose levels.
- c. Slow gastric emptying.
- d. Decrease glucose absorption from the gut.
Answer: b. Stimulate insulin secretion from pancreatic beta cells regardless of blood glucose levels.
28. An active learning session on diabetes is part of which course?
- a. PHA5787C Patient Care 5
- b. PHA5163L Professional Skills Lab 3
- c. PHA5781 Patient Care I
- d. PHA5782C Patient Care 2
Answer: a. PHA5787C Patient Care 5
29. The Somogyi effect is characterized by:
- a. High morning blood sugar due to a high bedtime snack.
- b. Rebound hyperglycemia in the morning following an episode of nocturnal hypoglycemia.
- c. A gradual rise in blood sugar from dawn until morning.
- d. Low blood sugar throughout the entire night.
Answer: b. Rebound hyperglycemia in the morning following an episode of nocturnal hypoglycemia.
30. The “Medicinal Chemistry of Diabetes Medications” is a topic within the Patient Care 5 curriculum.
- a. True
- b. False
Answer: a. True
31. A patient with Type 2 Diabetes and established atherosclerotic cardiovascular disease should be treated with which of the following, based on cardiovascular outcome trials?
- a. A sulfonylurea
- b. A GLP-1 receptor agonist or SGLT2 inhibitor with proven cardiovascular benefit.
- c. NPH insulin
- d. A DPP-4 inhibitor
Answer: b. A GLP-1 receptor agonist or SGLT2 inhibitor with proven cardiovascular benefit.
32. A patient experiences hypoglycemia (blood glucose 60 mg/dL). According to the “Rule of 15,” the patient should:
- a. Inject their long-acting insulin.
- b. Consume 15 grams of a simple carbohydrate and recheck their blood sugar in 15 minutes.
- c. Eat a meal high in fat and protein.
- d. Go for a brisk walk.
Answer: b. Consume 15 grams of a simple carbohydrate and recheck their blood sugar in 15 minutes.
33. The primary difference between DKA and HHS is that:
- a. DKA occurs in Type 2 Diabetes, and HHS occurs in Type 1 Diabetes.
- b. Significant ketoacidosis is present in DKA but is absent or minimal in HHS.
- c. Blood glucose levels are much lower in HHS than in DKA.
- d. Dehydration is not a feature of DKA.
Answer: b. Significant ketoacidosis is present in DKA but is absent or minimal in HHS.
34. Which of the following is a rapid-acting insulin?
- a. NPH
- b. Detemir
- c. Regular
- d. Aspart
Answer: d. Aspart
35. A pharmacist’s role in diabetes management includes:
- a. Medication therapy management (MTM).
- b. Patient education on medications, devices, and lifestyle.
- c. Improving medication adherence.
- d. All of the above.
Answer: d. All of the above.
36. A common side effect of metformin that can be minimized by slow titration and taking it with food is:
- a. Weight gain
- b. GI upset (diarrhea, nausea)
- c. Hypoglycemia
- d. Edema
Answer: b. GI upset (diarrhea, nausea)
37. Which insulin can be mixed in the same syringe with NPH insulin?
- a. Glargine
- b. Detemir
- c. Degludec
- d. Regular or rapid-acting insulins
Answer: d. Regular or rapid-acting insulins
38. The management of diabetes is an active learning session in the Patient Care 5 course.
- a. True
- b. False
Answer: a. True
39. A patient taking an SGLT2 inhibitor should be counseled on the risk of:
- a. Hyperkalemia
- b. Dehydration and genital mycotic infections.
- c. Weight gain.
- d. A persistent dry cough.
Answer: b. Dehydration and genital mycotic infections.
40. An active learning session covering diabetes is part of which course module?
- a. Module 1: Diabetes Mellitus
- b. Module 3: Women’s Health
- c. Module 4: Medication Safety
- d. Module 8: Men’s Health
Answer: a. Module 1: Diabetes Mellitus
41. Which of the following is a long-acting (basal) insulin?
- a. Lispro
- b. Glulisine
- c. Glargine
- d. Regular
Answer: c. Glargine
42. The pathophysiology of Type 1 Diabetes involves:
- a. An absolute deficiency of insulin.
- b. Severe insulin resistance.
- c. A relative deficiency of insulin.
- d. A deficiency of glucagon.
Answer: a. An absolute deficiency of insulin.
43. A key counseling point for a patient starting any sulfonylurea is:
- a. The need to take it with a high-fat meal.
- b. The signs and symptoms of hypoglycemia and how to treat it.
- c. That it will cause significant weight loss.
- d. To always take it at bedtime.
Answer: b. The signs and symptoms of hypoglycemia and how to treat it.
44. What is the role of A1c testing?
- a. It measures the average blood glucose over the past 2-3 months.
- b. It measures the blood glucose at a single point in time.
- c. It is used to diagnose hypoglycemia.
- d. It measures insulin levels.
Answer: a. It measures the average blood glucose over the past 2-3 months.
45. Which of the following is NOT a risk factor for Type 2 Diabetes?
- a. Obesity
- b. Family history
- c. A physically active lifestyle
- d. Age > 45 years
Answer: c. A physically active lifestyle
46. A patient is prescribed a “basal-bolus” insulin regimen. This is designed to:
- a. Be as simple as possible.
- b. Mimic the natural, physiologic pattern of insulin release.
- c. Be used only in Type 2 Diabetes.
- d. Prevent all episodes of hypoglycemia.
Answer: b. Mimic the natural, physiologic pattern of insulin release.
47. A patient with gastroparesis, a complication of diabetes, may benefit from which class of medication due to its effect on slowing gastric emptying?
- a. GLP-1 receptor agonists are generally avoided or used with caution in severe gastroparesis.
- b. Sulfonylureas
- c. Metformin
- d. Pioglitazone
Answer: a. GLP-1 receptor agonists are generally avoided or used with caution in severe gastroparesis.
48. An active learning session on diabetes is part of which course?
- a. PHA5787C Patient Care 5
- b. PHA5163L Professional Skills Lab 3
- c. PHA5781 Patient Care I
- d. PHA5782C Patient Care 2
Answer: a. PHA5787C Patient Care 5
49. The overall management of diabetes requires a team-based approach involving:
- a. The patient
- b. The physician or endocrinologist
- c. The pharmacist and diabetes educator
- d. All of the above
Answer: d. All of the above
50. The ultimate goal of managing diabetes is to:
- a. Use as many medications as possible.
- b. Prevent acute and chronic complications and improve the patient’s quality of life.
- c. Achieve an A1c of < 5.0% in all patients.
- d. Eliminate the need for blood glucose monitoring.
Answer: b. Prevent acute and chronic complications and improve the patient’s quality of life.
